WO2017211937A1 - Inhibiteur du récepteur flt3 à faible dose permettant le traitement de la douleur neuropathique - Google Patents

Inhibiteur du récepteur flt3 à faible dose permettant le traitement de la douleur neuropathique Download PDF

Info

Publication number
WO2017211937A1
WO2017211937A1 PCT/EP2017/063935 EP2017063935W WO2017211937A1 WO 2017211937 A1 WO2017211937 A1 WO 2017211937A1 EP 2017063935 W EP2017063935 W EP 2017063935W WO 2017211937 A1 WO2017211937 A1 WO 2017211937A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptor inhibitor
flt3 receptor
pain
neuropathic
treatment
Prior art date
Application number
PCT/EP2017/063935
Other languages
English (en)
Inventor
Jean Valmier
Original Assignee
Institut National De La Sante Et De La Recherche Medicale (Inserm)
Universite De Montpellier
Axlr Satt Du Languedoc Roussillon (Satt Axlr)
Biodol Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Sante Et De La Recherche Medicale (Inserm), Universite De Montpellier, Axlr Satt Du Languedoc Roussillon (Satt Axlr), Biodol Therapeutics filed Critical Institut National De La Sante Et De La Recherche Medicale (Inserm)
Priority to EP17727913.0A priority Critical patent/EP3468602B1/fr
Priority to US16/307,968 priority patent/US10709687B2/en
Priority to JP2018563716A priority patent/JP7134097B2/ja
Publication of WO2017211937A1 publication Critical patent/WO2017211937A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the allometric FDA factor for the rat is 6.2 and the allometric FDA factor for the mouse is 12.3.
  • the HED are typically calculated as the daily dose for a human with a body weight of 60 kg.
  • the active daily dosage per human adult of the said FLT3 receptor inhibitor used for the treatment of any type of cancer as used in method 1 is the highest known active daily dosage when various active dosages are known for different cancers.
  • Said approach may be applied to sunitinib.
  • EXAMPLE 2 Effects of sunitinib on capsaicin-induced increase of extracellular calcium in Dorsal Root Ganglia (DRG)

Abstract

La présente invention concerne un inhibiteur du récepteur FLT3 destiné à être utilisé dans le traitement de la douleur neuropathique et de la douleur chronique comprenant un constituant neuropathique, la plage posologique quotidienne par adulte humain par jour dudit inhibiteur du récepteur FLT3 consistant en une plage posologique déterminée par une méthode comprenant les étapes consistant : (i) à déterminer la dose d'inhibition minimale dudit inhibiteur du récepteur FLT3 qui induit l'inhibition maximale de l'hypersensibilité à la douleur mécanique, (ii) à convertir ladite dose en la dose équivalente humaine (DEH) par la méthode de correction allométrique, et (iii) à établir une plage posologique quotidienne par adulte humain par jour, (iii-1) la limite inférieure de ladite plage posologique quotidienne par adulte humain par jour correspondant à la valeur la plus élevée entre la valeur de DEH/20 telle que déterminée<i /> dans un modèle de rat et 0,001 mg, et (iii-2) la limite supérieure de ladite plage posologique quotidienne correspondant à la valeur la plus faible entre la valeur de HED*20 telle que déterminée<i /> dans un modèle de rat et 50 mg.
PCT/EP2017/063935 2016-06-08 2017-06-08 Inhibiteur du récepteur flt3 à faible dose permettant le traitement de la douleur neuropathique WO2017211937A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP17727913.0A EP3468602B1 (fr) 2016-06-08 2017-06-08 Inhibiteur du récepteur flt3 à faible dose pour le traitement d'une douleur neuropathique
US16/307,968 US10709687B2 (en) 2016-06-08 2017-06-08 FLT3 receptor inhibitor at low dosage for the treatment of neuropathic pain
JP2018563716A JP7134097B2 (ja) 2016-06-08 2017-06-08 神経障害性疼痛の治療のための低用量ｆｌｔ３受容体阻害剤

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16305669.0A EP3254698A1 (fr) 2016-06-08 2016-06-08 Inhibiteur du récepteur flt3 à faible dose pour le traitement d'une douleur neuropathique
EP16305669.0 2016-06-08

Publications (1)

Publication Number Publication Date
WO2017211937A1 true WO2017211937A1 (fr) 2017-12-14

Family

ID=56134285

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2017/063935 WO2017211937A1 (fr) 2016-06-08 2017-06-08 Inhibiteur du récepteur flt3 à faible dose permettant le traitement de la douleur neuropathique

Country Status (5)

Country Link
US (1) US10709687B2 (fr)
EP (2) EP3254698A1 (fr)
JP (1) JP7134097B2 (fr)
HU (1) HUE062092T2 (fr)
WO (1) WO2017211937A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020212395A1 (fr) * 2019-04-16 2020-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation d'inhibiteurs de jak pour le traitement d'états douloureux impliquant des canaux nav1.7
KR102231446B1 (ko) * 2021-01-21 2021-03-24 (주) 와이디생명과학 베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물
WO2023129667A1 (fr) 2021-12-30 2023-07-06 Biomea Fusion, Inc. Composés pyrazines utilisés comme inhibiteurs de flt3

Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032861A2 (fr) 2000-10-17 2002-04-25 Merck & Co., Inc. Sels oralement actifs a activite tyrosine kinase
WO2002092599A1 (fr) 2001-05-14 2002-11-21 Novartis Ag Derives 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine
WO2003024969A1 (fr) 2001-09-14 2003-03-27 Merck & Co., Inc. Inhibiteurs des tyrosine kinases
WO2003024931A1 (fr) 2001-09-14 2003-03-27 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
WO2003035009A2 (fr) 2001-10-26 2003-05-01 Sugen, Inc. Traitement de la leucemie myeloide aigue a l'aide de composes d'indolinone
WO2003037347A1 (fr) 2001-10-30 2003-05-08 Novartis Ag Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3
WO2003057690A1 (fr) 2001-12-27 2003-07-17 Theravance, Inc. Derives d'indolinone utilises comme inhibiteurs de la proteine kinase
WO2003099771A2 (fr) 2002-05-29 2003-12-04 Novartis Ag Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
WO2004005281A1 (fr) 2002-07-05 2004-01-15 Novartis Ag Inhibiteurs de tyrosine kinases
WO2004016597A2 (fr) 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Inhibiteurs de la proteine kinase et leurs utilisations
WO2004018419A2 (fr) 2002-08-23 2004-03-04 Chiron Corporation Quinolinones de benzimidazole et leurs utilisations
WO2004039782A1 (fr) 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Derives de quinoline et de quinazoline inhibant l'autophosphorylation de flt3 et compositions medicales les contenant
WO2004043389A2 (fr) 2002-11-13 2004-05-27 Chiron Corporation Procedes de traitement du cancer et procedes connexes
WO2004046120A2 (fr) 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles convenant comme inhibiteurs de proteine kinases
WO2004058749A1 (fr) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Derives de benzisoxazole utiles en tant qu'inhibiteurs des proteine kinases
WO2006138155A1 (fr) 2005-06-10 2006-12-28 Janssen Pharmaceutica N.V. Modulation synergique de kinase flt3 kinase au moyen d'un inhibiteur flt3 et d'un inhibiteur de farnesyl transferase
WO2007048088A2 (fr) 2005-10-18 2007-04-26 Janssen Pharmaceutica N.V. Methode d'inhibition de la kinase flt3
WO2007109120A2 (fr) 2006-03-17 2007-09-27 Ambit Biosciences Corporation Composés d'imidazolothiazole pour le traitement de maladies
WO2009061446A1 (fr) 2007-11-08 2009-05-14 Ambit Biosciences Corp. Procédés d'administration de n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-éthoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phényl}urée pour traiter une maladie proliférative
WO2009095399A2 (fr) 2008-02-01 2009-08-06 Akinion Pharmaceuticals Ab Nouveaux composés, leur utilisation et leur préparation
WO2011083124A1 (fr) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur flt3 destinés au traitement ou à la prévention de troubles douloureux
WO2016016370A1 (fr) * 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes des récepteurs flt3

Patent Citations (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002032861A2 (fr) 2000-10-17 2002-04-25 Merck & Co., Inc. Sels oralement actifs a activite tyrosine kinase
WO2002092599A1 (fr) 2001-05-14 2002-11-21 Novartis Ag Derives 4-amino-5-phenyl-7-cyclobutyl-pyrrolo (2,3-d) pyrimidine
WO2003024969A1 (fr) 2001-09-14 2003-03-27 Merck & Co., Inc. Inhibiteurs des tyrosine kinases
WO2003024931A1 (fr) 2001-09-14 2003-03-27 Merck & Co., Inc. Inhibiteurs de tyrosine kinase
WO2003035009A2 (fr) 2001-10-26 2003-05-01 Sugen, Inc. Traitement de la leucemie myeloide aigue a l'aide de composes d'indolinone
WO2003037347A1 (fr) 2001-10-30 2003-05-08 Novartis Ag Derives de staurosporine inhibiteurs de l'activite tyrosine kinase du recepteur flt3
WO2003057690A1 (fr) 2001-12-27 2003-07-17 Theravance, Inc. Derives d'indolinone utilises comme inhibiteurs de la proteine kinase
WO2003099771A2 (fr) 2002-05-29 2003-12-04 Novartis Ag Derives de diaryle-uree utilises pour le traitement des maladies dependant des proteines kinases
WO2004005281A1 (fr) 2002-07-05 2004-01-15 Novartis Ag Inhibiteurs de tyrosine kinases
WO2004016597A2 (fr) 2002-08-14 2004-02-26 Vertex Pharmaceuticals Incorporated Inhibiteurs de la proteine kinase et leurs utilisations
WO2004018419A2 (fr) 2002-08-23 2004-03-04 Chiron Corporation Quinolinones de benzimidazole et leurs utilisations
WO2004039782A1 (fr) 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Derives de quinoline et de quinazoline inhibant l'autophosphorylation de flt3 et compositions medicales les contenant
WO2004043389A2 (fr) 2002-11-13 2004-05-27 Chiron Corporation Procedes de traitement du cancer et procedes connexes
WO2004046120A2 (fr) 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles convenant comme inhibiteurs de proteine kinases
WO2004058749A1 (fr) 2002-12-18 2004-07-15 Vertex Pharmaceuticals Incorporated Derives de benzisoxazole utiles en tant qu'inhibiteurs des proteine kinases
WO2006138155A1 (fr) 2005-06-10 2006-12-28 Janssen Pharmaceutica N.V. Modulation synergique de kinase flt3 kinase au moyen d'un inhibiteur flt3 et d'un inhibiteur de farnesyl transferase
WO2007048088A2 (fr) 2005-10-18 2007-04-26 Janssen Pharmaceutica N.V. Methode d'inhibition de la kinase flt3
WO2007109120A2 (fr) 2006-03-17 2007-09-27 Ambit Biosciences Corporation Composés d'imidazolothiazole pour le traitement de maladies
WO2009061446A1 (fr) 2007-11-08 2009-05-14 Ambit Biosciences Corp. Procédés d'administration de n-(5-tert-butyl-isoxazol-3-yl)-n'-{4-[7-(2-morpholin-4-yl-éthoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phényl}urée pour traiter une maladie proliférative
WO2009095399A2 (fr) 2008-02-01 2009-08-06 Akinion Pharmaceuticals Ab Nouveaux composés, leur utilisation et leur préparation
WO2011083124A1 (fr) 2010-01-05 2011-07-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes du récepteur flt3 destinés au traitement ou à la prévention de troubles douloureux
WO2016016370A1 (fr) * 2014-07-31 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonistes des récepteurs flt3

Non-Patent Citations (29)

* Cited by examiner, † Cited by third party
Title
"Guidance for Industry - Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers U.S. Department of Health and Human Services", July 2005, FOOD AND DRUG ADMINISTRATION
"Merck Index"
BONNINGTON, J. K.; MCNAUGHTON, J. PHYSIOL, vol. 551, pages 433 - 446
BOUDES ET AL., J. NEUROSCI., vol. 29, no. 46, pages 10060 - 10068
BRITISH JOURNAL OF CANCER, vol. 112, 2015, pages 296 - 305
CRITICAL REV IN ONCOL/HEMATOL, vol. 94, 2015, pages 136 - 145
CRITICAL REV IN ONCOL/HEMATOL, vol. 94, 2015, pages 228 - 237
FABIAN ET AL., NAT BIOTECHNOL, vol. 23, 2005, pages 329 - 336
FEHRENBACHER ET AL.: "Curr Protoc Pharmacol.", March 2012
FINNERUP ET AL., LANCET NEUROL., vol. 14, 2015, pages 162 - 173
GATHALIA ET AL., CRITICAL REV IN ONCOL/HEMATOL, vol. 93, 2015, pages 257 - 276
IADAROLA ET AL., PAIN, vol. 35, 1988, pages 313 - 26
KARAMAN ET AL., NAT BIOTECHNOL, vol. 26, 2008, pages 127 - 132
KAYSER ET AL., BRAIN RES, vol. 508, 1990, pages 329 - 332
KIM; CHUNG, PAIN, vol. 50, 1992, pages 355 - 363
LANGE ET AL., BLOOD, vol. 70, 1987, pages 192 - 199
MASSEY ET AL., SUPPORT CARE CANCER, vol. 23, 2015, pages 1827 - 1835
O'FARRELL ET AL., BLOOD, vol. 101, 2003, pages 3597 - 3605
ROSNEY ET AL., ONCOGENE, vol. 6, 1991, pages 1641 - 1650
SANTONI ET AL., INT J CANCER, vol. 135, 2014, pages 763 - 773
STERNBERG ET AL., CURR OPIN HEMATOL, vol. 12, 2005, pages 7 - 13
SWEENEY ET AL: "A phase I study of sunitinib plus capecitabine in pateints with advanced solid tumors", J.CLIN.ONCOL., vol. 28, no. 29, 13 September 2010 (2010-09-13), pages 4513 - 4520, XP002763348, DOI: 10.1200/JCO.2009.26.9696 *
TERADA ET AL., PHARMACOLOGY & THERAPEUTICS, vol. 152, 2015, pages 125 - 134
TREEDE ET AL., NEUROLOGY, vol. 70, 2008, pages 1630 - 1635
US FOOD AND DRUG ADMINISTRATION'S GUIDANCE FOR INDUSTRY- ESTIMATING THE MAXIMUM SAFE STARTING DOSE IN INITIAL CLINICAL TRIALS FOR THERAPEUTICS IN ADULT HEALTHY VOLUNTEERS, July 2005 (2005-07-01)
US FOOD AND DRUG ADMINISTRATION'S GUIDANCE FOR INDUSTRY- ESTIMATING THE MAXIMUM SAFE STARTING DOSE IN INITIAL CLINICAL TRIALS FOR THERAPEUTICS IN ADULT HEALTHY VOLUNTEERS, July 2005 (2005-07-01), Retrieved from the Internet <URL:http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidan ces/UCM078932.pdf>
YOKOTA ET AL., LEUKEMIA, vol. 11, 1997, pages 1605 - 1609
YOUJIN ET AL., LANCET ONCOL, vol. 10, 2009, pages 967 - 74
ZARRINKAR ET AL., BLOOD, vol. 114, 2009, pages 2984 - 2992

Also Published As

Publication number Publication date
JP2019517536A (ja) 2019-06-24
US10709687B2 (en) 2020-07-14
EP3468602A1 (fr) 2019-04-17
US20190298691A1 (en) 2019-10-03
JP7134097B2 (ja) 2022-09-09
EP3468602B1 (fr) 2023-02-22
HUE062092T2 (hu) 2023-09-28
EP3254698A1 (fr) 2017-12-13

Similar Documents

Publication Publication Date Title
KR20200098536A (ko) Dux4 발현과 관련된 질병의 치료를 위한 화합물
KR102202481B1 (ko) 신규 용도
US10709687B2 (en) FLT3 receptor inhibitor at low dosage for the treatment of neuropathic pain
US10117890B2 (en) Methods and compositions for treating pain
EA030333B1 (ru) Способ лечения и/или предотвращения расстройств настроения
WO2022115798A2 (fr) Compositions et méthodes de traitement de la migraine
ES2649492T3 (es) (S)-pirlindol o sus sales farmacéuticamente aceptables para uso en medicina
Roni et al. Antidepressant-like effects of lobeline in mice: behavioral, neurochemical, and neuroendocrine evidence
JP5727642B2 (ja) センタキンを用いた新規の治療方法
Li et al. Inhibitors of the neutral amino acid transporters ASCT1 and ASCT2 are effective in in vivo models of schizophrenia and visual dysfunction
JP6959371B2 (ja) 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用
Inocêncio Leite et al. Topical antinociceptive effect of Vanillosmopsis arborea Baker on acute corneal pain in mice
JP2017505772A (ja) ｓｐａｄｉｎのレトロ−インベルソ類似体は増大された抗うつ作用を示す
KR102266696B1 (ko) 주의력 및 인지 장애, 및 신경 퇴행성 장애와 관련된 치매 치료용 신규 치료제
EP2138174A1 (fr) Composition pharmaceutique sous forme de comprimé sublingual comprenant un anti-inflammatoire non stéroïdien et un analgésique opiacé pour la gestion de la douleur
Lu et al. Insights into the central pathways involved in the emetic and behavioural responses to exendin-4 in the ferret
Uchiumi et al. Serotonergic involvement in the amelioration of behavioral abnormalities in dopamine transporter knockout mice by nicotine
Uzbay et al. Acute and chronic tianeptine treatments attenuate ethanol withdrawal syndrome in rats
Czyrak et al. Antidepressant activity of S-adenosyl-L-methionine in mice and rats
CN114010653B (zh) 包括人参皂苷Rg1和岩藻多糖的组合物在制备降低组织因子的表达的药物中的应用
ES2935705T3 (es) Un ligando del receptor GABA A
Liu et al. The potent analgesia of intrathecal 2R, 6R-HNK via TRPA1 inhibition in LF-PENS-induced chronic primary pain model
Okuda et al. Trazodone hydrochloride attenuates thermal hyperalgesia in a chronic constriction injury rat model
WO2014005721A1 (fr) Utilisation de (r)-phénylpiracétam pour le traitement de la fatigue associée à une maladie
Zhu et al. Non-adrenergic exploratory behavior induced by moxonidine at mildly hypotensive doses

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17727913

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2018563716

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2017727913

Country of ref document: EP

Effective date: 20190108